Jordan P Reynolds1, Raymond R Tubbs2, Eugen C Minca3, Stephen MacNamara2, Francisco A Almeida4, Patrick C Ma5, Nathan A Pennell5, Joseph C Cicenia4. 1. Department of Molecular Pathology, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States; Department of Anatomic Pathology, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States. Electronic address: Reynolj4@ccf.org. 2. Department of Molecular Pathology, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States. 3. Department of Molecular Pathology, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States; Department of Anatomic Pathology, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States. 4. The Respiratory Institute, Cleveland Clinic, Cleveland, OH, United States. 5. Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, United States.
Abstract
OBJECTIVES: Epidermal growth factor receptor (EGFR) gene mutation status should be determined in all patients with advanced, non-squamous non-small cell lung carcinoma (NSCLC) to guide targeted therapy with EGFR tyrosine kinase inhibitors. EGFR mutations are commonly tested by Sanger sequencing or allele specific polymerase chain reaction (ASPCR) on formalin-fixed paraffin-embedded (FFPE) samples including cell blocks (CB) that may fail due to absence of tumor cells. The cell pellet from cytology specimens obtained at the time of endobronchial guided ultrasound fine needle aspiration (EBUS FNA) (EBUS-TBNA, transbronchial needle aspiration) represents an alternative resource for additional tissue. Here we demonstrate the utility of using the FNA cell pellet versus for the detection of EGFR mutations in NSCLC. MATERIALS AND METHODS: For internal validation, 39 cytology samples from patients with NSCLC referred for EGFR testing were analyzed using the EGFR rotor-gene Q (RGQ) PCR assay (Qiagen). Thereafter, a consecutive series of 228 EBUS FNA samples were tested. RESULTS: The ASPCR assay demonstrated acceptable intra-assay, inter-assay and inter-lot reproducibility, sensitivity, and specificity. For the consecutive series, only 6/228 (2.6%) failed analysis (5 due to insufficient DNA yield). Of 228 EBUS FNA cell pellets tested 32 (14.0%) demonstrated clinically relevant mutations. RESULTS AND CONCLUSION: ASPCR can reliably detect EGFR gene mutations in FNA preparations from patients with NSCLC obtained at EBUS.
OBJECTIVES:Epidermal growth factor receptor (EGFR) gene mutation status should be determined in all patients with advanced, non-squamous non-small cell lung carcinoma (NSCLC) to guide targeted therapy with EGFR tyrosine kinase inhibitors. EGFR mutations are commonly tested by Sanger sequencing or allele specific polymerase chain reaction (ASPCR) on formalin-fixed paraffin-embedded (FFPE) samples including cell blocks (CB) that may fail due to absence of tumor cells. The cell pellet from cytology specimens obtained at the time of endobronchial guided ultrasound fine needle aspiration (EBUS FNA) (EBUS-TBNA, transbronchial needle aspiration) represents an alternative resource for additional tissue. Here we demonstrate the utility of using the FNA cell pellet versus for the detection of EGFR mutations in NSCLC. MATERIALS AND METHODS: For internal validation, 39 cytology samples from patients with NSCLC referred for EGFR testing were analyzed using the EGFR rotor-gene Q (RGQ) PCR assay (Qiagen). Thereafter, a consecutive series of 228 EBUS FNA samples were tested. RESULTS: The ASPCR assay demonstrated acceptable intra-assay, inter-assay and inter-lot reproducibility, sensitivity, and specificity. For the consecutive series, only 6/228 (2.6%) failed analysis (5 due to insufficient DNA yield). Of 228 EBUS FNA cell pellets tested 32 (14.0%) demonstrated clinically relevant mutations. RESULTS AND CONCLUSION: ASPCR can reliably detect EGFR gene mutations in FNA preparations from patients with NSCLC obtained at EBUS.
Authors: Laura Millares; Mireia Serra; Felipe Andreo; Jose Sanz-Santos; Concepción Montón; Carles Grimau; Miguel Gallego; Laia Setó; Neus Combalia; Mariona Llatjos; Rosa Escoda; Eva Castellà; Eduard Monsó Journal: Clin Exp Metastasis Date: 2015-06-29 Impact factor: 5.150
Authors: Maria-Rosa Ghigna; Adrian Crutu; Valentina Florea; Séverine Feuillet-Soummer; Pierre Baldeyrou; Julien Adam; Ludovic Lacroix; Benjamin Besse; Olaf Mercier; Elie Fadel; Peter Dorfmuller; Rida El Ayoubi; Vincent Thomas de Montpréville Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Sonja I Buschow; Matteo Ramazzotti; Gerold Schuler; Duccio Cavalieri; Carl G Figdor; Inge M J Reinieren-Beeren; Lucie M Heinzerling; Harm Westdorp; Irene Stefanini; Luca Beltrame; Stanleyson V Hato; Eva Ellebaek; Stefanie Gross; Van Anh Nguyen; Georg Weinlich; Jiannis Ragoussis; Dilair Baban; Beatrice Schuler-Thurner; Inge M Svane; Nikolaus Romani; Jonathan M Austyn; I Jolanda M De Vries Journal: Oncotarget Date: 2017-06-27